North America Transient Protein Expression Market Forecast to 2031 - Regional Analysis - by Product Type, Application, and End User

The North America transient protein expression market was valued at US$ 324.14 million in 2023 and is expected to reach US$ 518.73 million by 2031; it is estimated to register a CAGR of 6.1% from 2023 to 2031.

Surging Popularity of Precision Medicine Fuels North America Transient Protein Expression Market

With advancements in medical technologies, the use of molecular biology techniques has increased significantly in the development of various therapeutic or treatment modalities. Genomic transcriptomic information facilitates the discovery of biomarkers that find applications in monitoring diseases and predicting their risks, serving as a key principle in different therapeutic modalities.

The use of personalized or precision medicines has surged dramatically due to the availability of vast information on genetic variations existing among people. For instance, mRNA-mediated therapy is characterized by decreased immunogenicity, superior translation efficacy, enhanced stability, pharmaceutical safety, and transient protein expression, and only the modified mRNA is utilized for therapeutic application instead of incorporating the entire host genome.

Pharmaceutical and biotechnology industries have developed various innovative techniques to treat cancer and neurodegenerative diseases. The transient gene expression technique has aided in significant progress in research related to neurotrauma and neurodegenerative diseases, which has resulted in the introduction of precision medicines for these conditions. Technological advancements in epigenetics, genetics, and proteomics are also supporting the development of therapeutics for the treatment of various genetic and rare genetic diseases caused by single- and multiple-cell disorders.

The Precision Medicine Initiative launched in the US in 2015 enhanced the use of genetic engineering, genomics, and proteomics, thereby increasing the use of transient protein expression techniques. Thus, the continuous research and development activities and growing government initiatives to support precision medicine boost the adoption of transient protein expression techniques.

North America Transient Protein Expression Market Overview

The US is the largest market in the world for transient protein expression and is estimated to dominate during the forecast period. The market growth in the country is expected due to extensive research and development activities in the biopharmaceutical segment, a growing number of startups involved in protein expression, and the rising adoption of recombinant protein for therapeutic applications. In addition, the presence of various market leaders operating in the segments is contributing to the market expansion.

The US biotechnology industry is the largest in the world. Government support and investments from private-public sectors have significantly promoted the biotechnology industry in the country. Moreover, the biopharmaceutical segment is much developed and continuously seeking opportunities to enhance its portfolio. Companies such as Illumina, Inc; Regeneron Pharmaceuticals, Inc; Agilent Technologies, Inc; Vertex Pharmaceuticals, and Biogen Inc. have been constantly working in medicine, genetic research, and bioengineering fields; they have introduced several innovative healthcare products into the market.

Further, the COVID-19 pandemic served several growth opportunities for the transient protein expression market. Biotechnology companies strengthened their research studies to understand the genealogy, virality, and potentiality of the virus for developing vaccines and other therapeutic products with the help of transient protein expression; thus, the market for transient protein expression is projected to continue to grow during the forecast period due to the aforementioned factors.

North America Transient Protein Expression Market Revenue and Forecast to 2031 (US$ Million)

North America Transient Protein Expression Market Segmentation

The North America transient protein expression market is categorized into product type, application, end user, and country.

• Based on product type, the North America transient protein expression market is segmented into instruments, reagents, expression vectors, and competent cells. The instruments segment held the largest market share in 2023.
• In terms of application, the North America transient protein expression market is segmented into genomic research, gene therapy, bio production, cancer research, and drug development. The genomic research segment held the largest market share in 2023.
• Based on end user, the North America transient protein expression market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and clinical research organizations. The pharmaceutical and biotechnology companies segment held the largest market share in 2023.
• By country, the North America transient protein expression market is segmented into the US, Canada, and Mexico. The US dominated the North America transient protein expression market share in 2023.

Thermo Fisher Scientific Inc, Merck KGaA, QIAGEN NV, GenScript Biotech Corporation, Promega Corp, Takara Bio Inc, New England Biolabs, Agilent Technologies Inc, Mirus Bio LLC, Bio-Rad Laboratories Inc, Lonza Group AG, and MaxCyte Inc are some of the leading companies operating in the North America transient protein expression market.

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America transient protein expression market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the North America transient protein expression market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America transient protein expression market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.